Lipocine to Showcase Innovative Therapeutics at A.G.P.'s Annual Healthcare Event

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Inc. (NASDAQ: LPCN), a leading biopharmaceutical firm renowned for its innovative oral delivery technology, is set to make waves at A.G.P.'s Annual Healthcare Company Showcase. This event, scheduled for May 21, 2025, will be conducted virtually, providing broad accessibility for investors and healthcare professionals alike.

Presentation Details

The presentation will occur at 4:00 PM ET, and interested attendees can join through the following link: Webcast Link. Following the event, a recorded version of the presentation will also be available on Lipocine's official website in the Investors section.

About Lipocine

Lipocine Inc. focuses on leveraging its proprietary technology platform to enhance the efficacy of therapeutic agents through effective oral delivery. Currently, the company is cultivating a portfolio of promising drug candidates that tackle significant unmet medical needs across various markets.

Among Lipocine's significant developmental assets is LPCN 1154, an oral formulation of brexanolone aimed at addressing postpartum depression. Additionally, the company is advancing LPCN 2101, a candidate designed for epilepsy, and LPCN 2203, an oral treatment targeting essential tremors. These drug candidates represent the organization's commitment to creating safer and more patient-friendly therapeutic options.

Lipocine is also working on LPCN 2401, a novel anabolic androgen receptor agonist that functions as an adjunct to incretin mimetics, aimed at improving body composition for obesity management. Furthermore, LPCN 1148 stands out as a groundbreaking androgen receptor agonist prodrug for oral application, designed for managing symptoms related to liver cirrhosis.

In addition to these candidates, Lipocine is pursuing opportunities for collaboration for several other treatments, including strategies for preventing preterm birth with LPCN 1107 and managing issues associated with decompensated cirrhosis with LPCN 1148. The company is also focusing on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) with LPCN 1144.

One of Lipocine's notable successes is TLANDO, an oral testosterone product containing testosterone undecanoate. It has already received FDA approval for use in adult males suffering from testosterone deficiency, underscoring the company's efficacy and trust in the pharmaceutical industry.

Lipocine's strategy revolves around establishing partnerships that will augment its development pipeline, a move that will enhance its capability to bring its groundbreaking therapies to market. As this company continues to expand its reach, it remains at the forefront of delivering innovative healthcare solutions.

For additional details about Lipocine's extensive portfolio and ongoing projects, please visit their website at www.lipocine.com.

Conclusion

The upcoming presentation at A.G.P.'s Annual Healthcare Company Showcase is a significant opportunity for Lipocine to present its innovative approaches and therapeutic advancements to a global audience. With several promising drug candidates in the pipeline, Lipocine is poised to make significant contributions to the field of biopharmaceuticals, offering hope to patients in need of groundbreaking treatments.